Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: A report of 13 cases and review of the literature

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American journal of hematology/oncology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21439PMID 19507208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange

  2008cited by this paper
• Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

  2008cited by this paper
• Rituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literature

  2008cited by this paper
• Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

  2008cited by this paper
• Rituximab in the treatment of autoimmune haematological disorders

  2008cited by this paper
• Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13

  2007cited by this paper
• Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia

  2007cited by this paper
• Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura

  2007cited by this paper
• The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders

  2006cited by this paper
• Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disorders

  2006cited by this paper
• Prognostic value of inhibitory anti‐ADAMTS13 antibodies in adult‐acquired thrombotic thrombocytopenic purpura

  2006cited by this paper
• Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.

  2005cited by this paper
• Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

  2005cited by this paper
• Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

  2004cited by this paper
• Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

  2004cited by this paper
• Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

  2004cited by this paper
• Rituximab in patients with refractory thrombotic thrombocytopenic purpura

  2004cited by this paper
• Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab

  2003cited by this paper
• Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura

  2003cited by this paper
• Rituximab therapy for refractory thrombotic thrombocytopenic purpura.

  2002cited by this paper
• B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.

  2001cited by this paper
• United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange

  1998cited by this paper
• Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura

  1992cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper

• Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.

  2023cites this paper
• High Incidence of Thrombotic Thrombocytopenic Purpura Exacerbation Rate Among Patients With Morbid Obesity and Drug Abuse

  2021cites this paper
• Bleeding Associated with Thrombocytopenia

  2021cites this paper
• Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab

  2020cites this paper
• Blood Cell Disorders and the Nervous System.

  2020cites this paper
• Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents

  2020cites this paper
• Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura

  2020cites this paper
• Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura

  2020cites this paper
• Evaluation of clinical symptom, laboratory finding and prognosis in thrombotic thrombocytopenic purpura patient from 2010 t0 2017. A single-center retrospective study

  2020cites this paper
• Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

  2020cites this paper
• Autoimmune Clotting Dysfunction

  2020cites this paper
• Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.

  2019cites this paper
• Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis

  2018cites this paper
• 含利妥昔单抗联合方案治疗难治/复发血栓性血小板减少性紫癜10例临床分析

  2018cites this paper
• The Influence of Different Types of Physical Activity on The Redox Status of Scuba Divers

  2017cites this paper
• Thrombotic Thrombocytopenic Purpura: Etiopathogenesis, Diagnostics and Basic Principles of Treatment

  2017cites this paper
• Management of thrombotic thrombocytopenic purpura.

  2017cites this paper
• Thrombotic microangiopathies: Similar presentations, different therapies

  2017cites this paper
• Thrombotic thrombocytopenic purpura

  2017cites this paper
• Thrombotic thrombocytopenic purpura.

  2017cites this paper
• Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.

  2017cites this paper
• Bortezomib as a Salvage Therapy for Severe Refractory Thrombotic Thrombocytopenic Purpura

  2017cites this paper
• Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review

  2016cites this paper
• Rituximab‐refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib

  2016influential citation
• Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.

  2015cites this paper
• Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases

  2015cites this paper
• Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.

  2015influential citation
• How I Treat How I treat refractory thrombotic thrombocytopenic purpura

  2015cites this paper
• How I treat refractory thrombotic thrombocytopenic purpura.

  2015cites this paper
• Primary and Secondary Thrombotic Microangiopathy Referred to a Single Plasma Exchange Center for Suspected Thrombotic Thrombocytopenic Purpura: 2000-2011

  2015cites this paper
• A phase‐II sequential case‐series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab

  2015cites this paper
• Clinical and Therapeutic Studies of Acquired Thrombotic Thrombocytopenic Purpura in China

  2015cites this paper
• [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].

  2015cites this paper
• The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.

  2015cites this paper
• How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

  2014cites this paper
• Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

  2014cites this paper
• Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in 2014—Current Knowledge and Outcomes with Plasma Exchange

  2014cites this paper
• Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.

  2014cites this paper
• Acute and Chronic Immune Thrombocytopenia: Biology, Diagnosis, and Management

  2014cites this paper
• Diagnosing Thrombocytopenia in the Clinic

  2014cites this paper
• Purpura thrombotique thrombocytopénique au cours de la grossesse : une entité rare à ne pas méconnaître !

  2013cites this paper
• Púrpura trombótica trombocitopénica y lupus eritematoso sistémico: descripción de 1 caso. Análisis desde atención primaria

  2013cites this paper
• B-Cell Targeted Therapies in Autoimmune Cytopenias and Thrombosis

  2013cites this paper
• 323 Microangiopathic Hemolytic Anemias

  2012cites this paper
• Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis

  2012cites this paper
• Microangiopathic Hemolytic Anemias

  2012cites this paper
• Thrombotic Microangiopathy in Haematopoietic Stem Cell Transplantation

  2012cites this paper
• Púrpura trombótica trombocitopénica

  2011cites this paper
• Chapitre 12 – Microangiopathies Thrombotiques

  2011cites this paper
• [Thrombotic thrombocytopenic purpura].

  2011cites this paper
• Thrombotic Thrombocytopenic Purpura

  2011cites this paper
• Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura.

  2011cites this paper
• Investigational drugs in thrombotic thrombocytopenic purpura

  2011cites this paper
• Rituximab therapy for autoimmune haematological diseases.

  2011cites this paper
• Anti‐CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders

  2011cites this paper
• Long-term Efficacy of Rituximab Treatment in Thrombotic Thrombocytopenic Purpura

  2011cites this paper
• Thrombotic thrombocytopenic purpura with severe neurological impairment: remission after Rituximab

  2011cites this paper
• Long-term response to rituximab in patients with relapsing thrombotic thrombocytopenic purpura.

  2011cites this paper
• [Response to rituximab in two patients with plasma exchange-refractory thrombotic thrombocytopenic purpura].

  2011cites this paper
• ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes

  2010cites this paper
• ASH 2009 meeting report—Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders

  2010cites this paper
• ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic lymphocytic leukemia

  2010cites this paper
• Systemischer Lupus erythematodes und Antiphospholipid-Syndrom

  2010cites this paper
• ASH 2009 meeting report—Top 10 clinically oriented abstracts in multiple myeloma

  2010cites this paper
• The Use of Rituximab in Immune-mediated Anaemia

  2010cites this paper
• A Case of Rituximab-Induced Hepatitis

  2010cites this paper
• How I treat patients with thrombotic thrombocytopenic purpura: 2010.

  2010influential citation
• ASH 2009 meeting report—Top 10 clinically oriented abstracts in sickle cell disease

  2010cites this paper
• Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies

  2010cites this paper
• ASH 2009 meeting report—Top 10 clinically‐oriented abstracts in hematopoietic stem cell transplantation

  2010cites this paper
• Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab

  2010cites this paper
• Rituximab in autoimmune hematologic diseases: not just a matter of B cells.

  2010cites this paper
• Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: the role of rituximab

  2010cites this paper
• Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report

  2010cites this paper
• Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP.

  2010cites this paper
• Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis.

  2010cites this paper